2021 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy
Recorded On: 01/20/2021
This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended. We will conclude with a twenty-minute discussion on the gaps in current knowledge, whether and how the practice can be individualized.
Rachel Wen-Juei Jeng, MD received her Doctor of Medicine Education from College of Medicine, National Yang-Ming University, Taiwan (1998-2005). She has accomplished internal medicine residency, Gastroenterology fellowship training and becomes a faculty and physician scientist in Department of Gastroenterology and Hepatology in Chang Gung Memorial Hospital, Linkou branch, Taiwan. She currently serves as an Associate Professor in College of Medicine, Chang Gung University since 2019.
Dr. Jeng’s research interests mainly focus on viral hepatitis (esp. HBV) and clinical hepatology. She has been working with her mentor Prof. Yun-Fan Liaw and published a series of off-Nuc therapy cohort study in Hepatology and Clinical Gastroenterology and HEPATOLOGY. She now serves as a member of TASL, EASL and AASLD.
Harry Janssen, MD, PhD, FAASLD is a professor of medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in hepatology. He currently works at Toronto General Hospital as chief of hepatology and director of the Toronto Centre for Liver Disease.
Dr. Janssen graduated from medical school in the Netherlands. During his study he spent one year as research student in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in hepatitis B. Following his training in Internal Medicine and Gastroenterology in the Netherlands, he returned to the Mayo Clinic for a Research Fellowship in Hepatology. In 2001, he became a faculty member and in 2006 he was appointed as full professor of medicine and chief of the Section Liver Diseases and Transplantation in Rotterdam. In 2013, he came to Canada where he merged three liver programs into the Toronto Centre for Liver Disease, based at the Toronto General Hospital, University Health Network.
Dr. Janssen has coordinated numerous clinical and translational studies on treatment for chronic viral hepatitis and other liver diseases. His main research interest is cure of chronic hepatitis B. He has published more than 500 original peer-reviewed papers and many book chapters. His H-index is over 100 and he has been cited 45,000 times (Google Scholar). He has received several prestigious international awards and has mentored over 50 PhD students, of whom many have taken leadership positions in the field of hepatology or virology.
Marc Ghany (Moderator)
Marc G. Ghany, MD, MHSc, FAASLD is an investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis.
Yao-Chun Hsu (Moderator)
Yao-Chun Hsu, MD, MSc, PhD is currently an associate professor at the school of medicine, I-Shou University, and the director of the Center for Liver Diseases, E-Da Hospital, both of which were in Kaohsiung, Taiwan. He is an active physician with a large clinical practice in inpatient and outpatient care, as well as sonography and endoscopy service. He is also an active researcher in clinical and translational research for chronic liver diseases, with a focus on chronic viral hepatitis, particularly viral hepatitis B. He has more than 100 peer-reviewed publications to his credit, including first authorship of original research articles published in leading journals such as Lance Infectious Diseases, Lancet Gastroenterology and Hepatology, Gut, Journal of Hepatology and HEPATOLOGY.
Dr. Hsu has served as an associate editor in the liver section for Digestive Diseases since 2018 and has joined the editorial board for Journal of Gastroenterology and Hepatology since 2017. He leads the research team for chronic viral hepatitis in E-Da Hospital and takes part in more than 10 multicenter trials as the principal investigator at his site. Moreover, he is eagerly participating in international collaboration and has been actively working with researchers from the United States, Canada, Japan, China, Hong Kong, and so on. His academic contributions have been recognized with awards such as the 28th Professor Sung Juei-Low's Academic Award for Excellent Research, Annual Research Award for Liver Disease Prevention and Treatment (awarded by the Taiwan Liver Disease Prevention & Treatment Research Foundation), and Young Investigator Award at the Asian Pacific Association for the Study of the Liver Single Topic Conference.